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In the context of biomarkers, antibodies fall into four main cate-
gories, each of which carries a different level of risk from an eco-
nomic development point of view (Fig. 1). Those markers used for
routine diagnostic purposes entail little or no risk, and prognostic
markers involve high risk. Predictive markers associated with
established therapies are low risk whereas those for new thera-
pies involve high risk.
The focus of the presentation was on development of antibod-
ies for detecting cancer biomarkers. It is crucial to use prospec-
tively defined criteria to select patients who are most likely to
respond to a specific molecularly targeted therapy. Proper patient
selection enables efficient clinical trial design for targeted thera-
pies and ensures that the number of individuals exposed to the
risks of anticancer therapy is minimised.
Patient selection can be facilitated through the use of systems,
such as pharmDx, Dako’s complete diagnostic assays that enable
selection of patients more likely to benefit from targeted therapy.
Herceptest was the first such system developed. It is used to
identify patients whose tumours overexpress Her-2/ERB2 and,
therefore, who would be mostly likely to respond to treatment
with trastuzumab (Herceptin), a humanised antibody targeting
the HER-2 receptor. By screening with the pharmDx system, the
response rate is greater than if the general patient population
were treated with trastuzumab. Semiquantitative scaling was
used for registration of the pharmDx technique and is the basis
for its labelling.
The quality of antibodies under development in terms of sen-
sitivity and specificity is extremely important. Antibodies can be
developed internally or acquired from external sources, usually
from the university research community. No matter how antibod-
ies are developed, they must be of the best quality with no toler-
ance for variation between batches.
Screening systems are required to ensure quality and
researchers use additional quality testing to ensure that the anti-
bodies actually recognise the specific moieties. Epitope mapping
is necessary to ensure specificity. Many antibodies on the market
have different specificities; this fact must be taken into account
when using them to select patients. The shelf life of Dako anti-
bodies is usually about 2 years. Detection of activated (phosphor-
ylated) proteins has received increasing interest during the last
few years. It is challenging to develop phospho-specific antibod-
ies that do not display cross-reactions with the backbone
sequence. The specificity, functionality, and the absence of
cross-reactions are verified by different methodologies to ensure
quality and performance of antibodies.
The antibodies must work on different types of tissues. This
needs to be confirmed by testing in multi-tissue arrays to make
sure that background staining is not problematic. The final step
is standardization of the assay to ensure consistency across
laboratories.
In conclusion, the keys to successful development of antibod-
ies for use in patient selection are high quality – in terms of spec-
ificity, functionality, and sensitivity – and standardisation of
reagents (no batch-to-batch variation), automated protocols,
and use of imaging as a means of interpreting the response.
Developing antibody-based testing for biomarkers is a high-risk
area, but the potential benefits are significant. Regulatory author-
ities throughout the world strongly advocate standardization of
testing to minimise the number of patients who experience
adverse side effects from treatment. Proper patient selection
can also optimise treatment expenditures by selecting the patient
population most likely to respond.
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The goal of incorporating biomarkers into cancer treatment and
clinical trials is to manage a patient’s disease by administering
effective and well-tolerated therapies, based on an understanding
of the patient’s unique genetic and molecular profile. For targeted
therapies that might only benefit a proportion of patients, failure
to select patients correctly has the potential to dilute trial out-
comes. Challenges in identifying those patients most likely to
benefit might risk wrongly concluding that therapeutically bene-
ficial drugs are ineffective.
There are many types of biomarkers of potential interest in
the field of targeted anticancer therapy. These can mainly be
divided into those that present in histopathological tissues and
blood-borne biomarkers. Significant advances in imaging (e.g.,
positron emission tomography [PET] scans) have also improved
the ability to monitor treatment effects. The focus of the presen-
tation was on acquisition of histopathological tissues.
GEFITINIB (IRESSA) CLINICAL DEVELOPMENT: The clinical
development of gefitinib, an orally-available epidermal growth
factor tyrosine kinase inhibitor (EGFR TKI) was reviewed: Phase I
and II development showed dramatic and unexpected tumour
regressions in approximately 10% of patients with advanced
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Fig. 1 – Strategies and challenges for cancer biomarker and
antibody development.
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non-small-cell lung cancer (NSCLC). Data from early-phase trials
did not show a clear correlation between patient outcome and
EGFR expression in archived tissue.1 Subsequently, however, data
emerged indicating that EGFR mutations and increased gene copy
number, as measured by fluorescence in situ hybridisation (FISH)
are associated with clinical response to gefitinib treatment.2–5
Other potential biomarkers of gefitinib outcome have also been
identified.
One of the challenges in the development of gefitinib was that
knowledge of potential biomarkers emerged during the conduct
of the pivotal trials. Indeed, increased EGFR gene copy number
measured by FISH was shown in 2003 to be a prognostic bio-
marker for outcome after surgery in patients with NSCLC,3 and
subsequently shown to be predictive of response to gefitinib.4 In
2004, EGFR mutations also emerged as predictors of response to
EGFR TKIs in patients with advanced NSCLC.5
Evolution of biomarkers during the conduct of large random-
ised trials might become the rule rather than the exception.
Although initial candidate biomarkers are evaluated early in
development, knowledge increases exponentially as research
and clinical experience become more widespread and increased
clinical data with which to correlate the translational work
becomes available.
THE CRITICAL IMPORTANCE OF TISSUE SAMPLES: The IRESSA
Survival Evaluation in Lung Cancer (ISEL) phase III trial high-
lighted many of the challenges in acquiring tissue samples in
large multinational randomised phase III trials. The phase I stud-
ies of gefitinib involved collaboration of just a few academic cen-
tres that were very devoted to collecting tissues. In phase II, 40
centres were involved, but the sample acquisition rate dropped
to 80%. The ISEL phase III study accrued very quickly worldwide,
but only 33% of patients’ samples were available (Fig. 1). Of these,
177 samples were evaluable for all three of the following biomark-
ers: FISH, EGFR expression and EGFR mutations.
Dr. Botwood outlined the challenges encountered in collecting
tissues for such studies. In ISEL, more than 25% of tissue samples
were inadequate (insufficient quantity or fixation) for any sort of
analysis, more than 60% were inadequate for mutational studies,
and 80% required remounting. Documentation of samples also
proved to be quite challenging as many were incorrectly labelled
and could not be validated.
The informed consent process also presented some chal-
lenges with fewer than 40% of patients consenting to tissue sam-
pling overall. Local changes to, and interpretation of, the consent
by ethics committees internationally also meant that it was not
possible to analyse all available samples from all countries.
Genetic testing is a critical consideration for informed consent.
Dr. Botwood emphasised the need for consent documents to ade-
quately explain the difference between hereditary and somatic
mutations (i.e. tumour-specific mutations that are not part of the
host’s genome). Investigatorsmust beprepared to respond toques-
tions from regulators and ethics boards in this regard.
PATHOLOGISTS AS RESEARCH PARTNERS: Acquisition of tissue
samples is increasingly central to research molecularly targeted
therapies. Protocols should be developed with tissue collection
and analysis in mind. Pathologists are critical partners in clinical
trials to ensure that samples are properly fixed, labelled and
shipped.
The situation is complex because security is a key concern to
pathologists when providing samples to investigators outside
their institutions. Therefore, every measure should be taken to
ensure that samples are promptly returned to pathologists, as
necessary, and their contributions should be recognised as co-
investigators. A study-initiation visit should be undertaken to
offer pathologists clear guidance on what is needed, with an
emphasis on the importance of biomarker work.
In terms of documentation, case report forms and requisition
documents should be complete and clear and should adhere to
data-reporting and protection provisions of the study protocol.
Documents should be subject to 100% source and data validation.
The data management plan for biomarkers should include such
issues as format, transfer and destination.
CHALLENGES ASSOCIATED WITH TISSUE SAMPLES: A host of
regulatory, ethical, and cultural challenges must be overcome.
Dr. Botwood pointed out that routine clinical practice does not
necessarily generate the samples required for biomarker analysis.
Many referral centres lack functioning systems for obtaining
research samples. Some countries prohibit export of DNA-con-
taining material, and several have a cultural preference for con-
ducting their own national research. Some countries prohibit
‘genetic’ analyses and do not make a clear distinction between
host and tumour research. Regulations on this are continually
evolving; what is permissible today might not be tomorrow.
Dr. Botwood noted that 95% of patients in the INVITE trial, a
randomised phase II study of gefitinib versus vinorelbine, provided
tumour samples, as provision of a tissue sample was mandatory
requirement for trial entry. In the IMEX trial comparing gefitinib
and methotrexate for treatment of head and neck cancer, 56% of
patients provided tumour samples, most of which were evaluable.
In this and other studies, an implicit assumption is made that the
diagnostic biopsy reflects current tumour status. This is not neces-
sarily the case however, as tumours and their markers evolve dur-
ing subsequent therapies. In addition, while markers of disease
progression are also potentially very interesting, re-biopsy at this
time is very challenging to patients.
MOVING FORWARD: Obtaining samples from multicentre, mul-
tinational phase III trials is complex because sample quality var-
ies and informed consent processes present different challenges
in different countries. Novel assays should ideally be carried out
at a single institution, or if this is not possible, by locally-vali-
dated laboratories. Assays that can be carried out on cytology or
blood specimens are preferable to tissue biopsies.
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Fig. 1 – Collecting markers in phase III was more difficult
than earlier phase trials of gefitinib in NSCLC patients.
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